Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls

By sjmartinez • March 12, 2024

Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls. EBioMedicine. 2024 Mar 7:105042. doi: 10.1016/j.ebiom.2024.105042. Epub ahead of print. PMID: 38471990.

Tags: Antiviral treatment, clinical trials, covid-19, General Internal Medicine, Mitochondrial antioxidants, Post-exposure prophylaxis, Publications, SARS-CoV-2 infection, Translational research

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide

Dao KT, Dhillon A, Uddin SS, Eppanapally S, Lai H. A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide. J[...]

Advancements in Spinal Cord Injury Rehabilitation

Eapen BC. Advancements in Spinal Cord Injury Rehabilitation. Phys Med Rehabil Clin N Am. 2025 Feb;36(1):xiii-xiv. doi: 10.1016/j.pmr.2024.09.002. Epub 2024 Oct 18. PMID: 39567042.

Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation

Wei MY, Tseng CH, Kang AJ. Higher-order disease interactions in multimorbidity measurement: marginal benefit over additive disease summation. J Gerontol A Biol Sci Med Sci.[...]